For EGFR-mutant NSCLC, the incidence of leptomeningeal disease has been reported to be higher than that of wild-type EGFR cohorts (9.4% versus 1.7%).74 Fortunately, osimertinib appears to be active in this setting as described in the phase I BLOOM trial, which reported a leptomeningeal ORR of 62% according to RANO criteria and complete cytologic clearance from the CSF in 28% of patients receiving osimertinib 160 mg daily.75 Notably, response rates were numerically similar (55% versus 57%) in patients receiving or not receiving prior intracranial radiotherapy. Here, EGFR is linked to non-small cell lung carcinoma.